GalChimia to Work with HQL Pharmaceuticals for Cancer Research

Under the agreement HQL will use its proprietary computational platform for screening chemical libraries that cover diverse chemotypes.

GalChimia, a Spanish provider of synthetic organic chemistry services, has announced to work with HQL Pharmaceuticals for cancer research.

The firm said it would work with the Israeli drug discovery firm to develop small molecules that cause programmed cell death by inhibiting protein-protein interactions targeting apoptotic pathways, which is said to play a key role in oncology.

GalChimia chief executive Carme Pampin said the firm has demonstrated its commitment with pharma and biotech companies to help accelerate drug discovery efforts and three firms are now advancing compounds to Phase I using the chemistry it has developed.

Under the agreement H